Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the

Umberto Malapelle1, Lucia Anna Muscarella2, Pasquale Pisapia1

  • 1Department of Public Health, "Federico II" University of Naples, Naples, Italy.

Expert Opinion on Investigational Drugs
|February 20, 2020
PubMed

Insights

Emerging molecular targets are crucial for advanced non-small-cell lung cancer (NSCLC). Research focuses on identifying new driver mutations and resistance mechanisms to improve tyrosine kinase inhibitor (TKI) therapies for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Driver molecular aberrations (e.g., EGFR, BRAF, ALK, ROS1) are key in non-small-cell lung cancer (NSCLC) oncogenesis.
  • Current tyrosine kinase inhibitors (TKIs) target specific mutations in about 20% of advanced nonsquamous NSCLC patients.
  • Novel driver mutations are critical for cancer growth and acquired resistance to existing TKIs.

Purpose of the Study:

  • To review emerging molecular targets in advanced stages of clinical development for NSCLC management.
  • To discuss the role of these targets in intrinsic and acquired resistance mechanisms.
  • To highlight the need for improved detection methods and clinical trials.

Main Methods:

  • Systematic review of peer-reviewed literature from bibliographic databases.
  • Analysis of data presented at key scientific meetings.
  • Focus on advanced stage clinical development.

Main Results:

  • Numerous emerging driver mutations are under investigation for metastatic NSCLC.
  • These mutations are implicated in both primary cancer development and resistance to prior therapies.
  • Therapeutic strategies for these emerging targets are actively being explored.

Conclusions:

  • Identifying and characterizing novel driver mutations is essential for advancing NSCLC treatment.
  • Understanding resistance mechanisms is crucial for developing effective therapeutic strategies.
  • Further preclinical and clinical research is required to optimize TKI therapy and improve patient benefit.
Keywords:
HER2METNRG1NTRKNon small cell lung cancerRETgene fusionsrare mutationsresistance mechanisms

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

264
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K